Miller Karen, Hall Brian, Tobias Joseph D
The Ohio State University College of Medicine, Ohio, USA.
Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Ohio, USA.
Ann Card Anaesth. 2017 Jul-Sep;20(3):376-378. doi: 10.4103/aca.ACA_15_17.
Sugammadex is a novel agent for the reversal of neuromuscular blockade. The speed and efficacy of reversal with sugammadex are significantly faster than acetylcholinesterase inhibitors, such as neostigmine. Sugammadex also has a limited adverse profile when compared with acetylcholinesterase inhibitors, specifically in regard to the incidence of bradycardia. This adverse effect may be particularly relevant in the setting of a heart transplant recipient with a denervated heart. The authors present a case of an 8-year-old child, status postcardiac transplantation, who required anesthetic care for laparoscopy and lysis of intra-abdominal adhesions. Sugammadex was used to reverse neuromuscular blockade and avoid the potential adverse effects of neostigmine. The unique mechanism of action of sugammadex is discussed, previous reports of its use in this unique patient population are reviewed, and its potential benefits compared to traditional acetylcholinesterase inhibitors are presented.
舒更葡糖钠是一种新型的用于逆转神经肌肉阻滞的药物。舒更葡糖钠逆转神经肌肉阻滞的速度和效果明显快于乙酰胆碱酯酶抑制剂,如新斯的明。与乙酰胆碱酯酶抑制剂相比,舒更葡糖钠的不良反应也较少,特别是在心动过缓的发生率方面。这种不良反应在心脏移植受者且心脏去神经支配的情况下可能尤为相关。作者报告了一例8岁心脏移植术后患儿,因腹腔镜检查和腹腔粘连松解术需要麻醉护理。使用舒更葡糖钠逆转神经肌肉阻滞,避免新斯的明的潜在不良反应。讨论了舒更葡糖钠独特的作用机制,回顾了此前关于其在这一特殊患者群体中应用的报道,并介绍了其与传统乙酰胆碱酯酶抑制剂相比的潜在益处。